A Study of Flt3-Ligand Levels in Sjögrens Syndrome

Completed

• Conditions: Sjogrens Syndrome

• Registration Number: NCT01470638
• Lead Sponsor: Göteborg University

Brief Summary

The study aims to correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Detailed Description

The study aims to correlate levels of Flt3-ligand in CSF and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Study Timeline

• Study Start: 2009-06
• Study First Submitted: 2011-11-09
• Study First Submitted QC: 2011-11-10
• Study First Posted: 2011-11-11
• Status Verified: 2019-04
• Primary Completion: 2019-04
• Study Completion: 2019-04
• Last Update Submitted: 2019-04-23
• Last Update Posted: 2019-04-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• fulfill the ACR-criteria for primary Sjogrens syndrome,
• age above 18 years old

Read More

Exclusion Criteria

• other CNS-disease

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome	June 2009 - June 2015

Trial Locations

Locations (1)

Dept of Rheumatology, Sahlgrenska University Hospital; 🇸🇪 Gothenburg, Sweden